CT-388
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
Roche · Phase 2 · Completed · Enrollment 447
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Arm 1: Placebo | n/r | n/r | n/r | n/r |
| Arm 2: Enicepatide Dose Level 1 (Low) | n/r | n/r | n/r | n/r |
| Arm 3: Enicepatide Dose Level 2 | n/r | n/r | n/r | n/r |
| Arm 4: Enicepatide Dose Level 3 | n/r | n/r | n/r | n/r |
| Arm 5: Enicepatide Dose Level 4 (High) | n/r | n/r | n/r | n/r |
Not shown
- Arm 1: Placebo: endpoint not reported
- Arm 2: Enicepatide Dose Level 1 (Low): endpoint not reported
- Arm 3: Enicepatide Dose Level 2: endpoint not reported
- Arm 4: Enicepatide Dose Level 3: endpoint not reported
- Arm 5: Enicepatide Dose Level 4 (High): endpoint not reported